Age at Seroconversion, HLA Genotype, and Specificity of Autoantibodies in Progression of Islet Autoimmunity in Childhood
- PMID: 31120497
- DOI: 10.1210/jc.2019-00421
Age at Seroconversion, HLA Genotype, and Specificity of Autoantibodies in Progression of Islet Autoimmunity in Childhood
Abstract
Context: Children with initial autoantibodies to either insulin (IAA) or glutamic acid decarboxylase (GADA) differ in peak age of seroconversion and have different type 1 diabetes (T1D) risk gene associations, suggesting heterogeneity in the disease process.
Objective: To compare the associations of age at seroconversion, HLA risk, and specificity of secondary autoantibodies with the progression of islet autoimmunity between children with either IAA or GADA as their first autoantibody.
Design and methods: A cohort of 15,253 children with HLA-associated increased risk of T1D participated in a follow-up program in which islet autoantibodies were regularly measured. The median follow-up time was 6.7 years. Spearman correlation, Kaplan-Meier survival plots, and Cox proportional-hazard models were used for statistical analyses.
Results: Persistent positivity for at least one of the tested autoantibodies was detected in 998 children; 388 of children progressed to clinical T1D. Young age at initial seroconversion was associated with a high probability of expansion of IAA-initiated autoimmunity and progression to clinical diabetes, whereas expansion of GADA-initiated autoimmunity and progression to diabetes were not dependent on initial seroconversion age. The strength of HLA risk affected the progression of both IAA- and GADA-initiated autoimmunity. The simultaneous appearance of two other autoantibodies increased the rate of progression to diabetes compared with that of a single secondary autoantibody among subjects with GADA-initiated autoimmunity but not among those with IAA as the first autoantibody.
Conclusions: Findings emphasize the differences in the course of islet autoimmunity initiated by either IAA or GADA supporting heterogeneity in the pathogenic process.
Copyright © 2019 Endocrine Society.
Similar articles
-
Characterisation of rapid progressors to type 1 diabetes among children with HLA-conferred disease susceptibility.Diabetologia. 2017 Jul;60(7):1284-1293. doi: 10.1007/s00125-017-4258-7. Epub 2017 Mar 31. Diabetologia. 2017. PMID: 28364254
-
Hierarchical Order of Distinct Autoantibody Spreading and Progression to Type 1 Diabetes in the TEDDY Study.Diabetes Care. 2020 Sep;43(9):2066-2073. doi: 10.2337/dc19-2547. Epub 2020 Jul 8. Diabetes Care. 2020. PMID: 32641373 Free PMC article.
-
Characteristics of Slow Progression to Type 1 Diabetes in Children With Increased HLA-Conferred Disease Risk.J Clin Endocrinol Metab. 2019 Nov 1;104(11):5585-5594. doi: 10.1210/jc.2019-01069. J Clin Endocrinol Metab. 2019. PMID: 31314077
-
Humoral beta-cell autoimmunity in relation to HLA-defined disease susceptibility in preclinical and clinical type 1 diabetes.Am J Med Genet. 2002 May 30;115(1):48-54. doi: 10.1002/ajmg.10343. Am J Med Genet. 2002. PMID: 12116176 Review.
-
Possible heterogeneity of initial pancreatic islet beta-cell autoimmunity heralding type 1 diabetes.J Intern Med. 2023 Aug;294(2):145-158. doi: 10.1111/joim.13648. Epub 2023 May 14. J Intern Med. 2023. PMID: 37143363 Free PMC article. Review.
Cited by
-
Progression of type 1 diabetes from latency to symptomatic disease is predicted by distinct autoimmune trajectories.Nat Commun. 2022 Mar 21;13(1):1514. doi: 10.1038/s41467-022-28909-1. Nat Commun. 2022. PMID: 35314671 Free PMC article.
-
Distinct cellular immune responses in children en route to type 1 diabetes with different first-appearing autoantibodies.Nat Commun. 2024 May 7;15(1):3810. doi: 10.1038/s41467-024-47918-w. Nat Commun. 2024. PMID: 38714671 Free PMC article.
-
Stratifying risk for onset of type 1 diabetes using islet autoantibody trajectory clustering.Diabetologia. 2023 Mar;66(3):520-534. doi: 10.1007/s00125-022-05843-x. Epub 2022 Nov 30. Diabetologia. 2023. PMID: 36446887 Free PMC article.
-
Islet Autoantibody Levels Differentiate Progression Trajectories in Individuals With Presymptomatic Type 1 Diabetes.Diabetes. 2022 Dec 1;71(12):2632-2641. doi: 10.2337/db22-0360. Diabetes. 2022. PMID: 36112006 Free PMC article.
-
Modeling cell-mediated immunity in human type 1 diabetes by engineering autoreactive CD8+ T cells.Front Immunol. 2023 May 30;14:1142648. doi: 10.3389/fimmu.2023.1142648. eCollection 2023. Front Immunol. 2023. PMID: 37325626 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials